Serum Lipids, Insulin-Like Growth Factor Binding Protein-3 and Treatment Outcomes in Women with and without Cervical Lesions in South Western Uganda: A Cohort Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca a Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, et al. ICO/IARC information centre on HPV and cancer (HPV information centre). Hum Papillom Rel Dis World Summ Rep. 2019;17:6.
   Google Scholar
• Ronco G, Montanari G, Aimone V, et al. Estimating the sensitivity of cervical cytology: errors of interpretation and test limitations. Cytopathology. 1996;7(3):151–158. doi:10.1046/j.1365-2303.1996.39382393.x
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessing National Capacity for the Prevention and Control of Noncommunicable Diseases: Report of the 2019 Global Survey. World Health Organization; 2020.
   Google Scholar
• Anorlu RI. Cervical cancer: the sub-Saharan African perspective. Rep Health Matters. 2008;16(32):41–49. doi:10.1016/S0968-8080(08)32415-X
   PubMed Web of Science ®Google Scholar
• Denny L, Quinn M, Sankaranarayanan R. Screening for cervical cancer in developing countries. Vaccine. 2006;24:S71–S7. doi:10.1016/j.vaccine.2006.05.121
   Web of Science ®Google Scholar
• Sankaranarayanan R. Screening for cancer in low-and middle-income countries. Anna Global Health. 2014;80(5):412–417. doi:10.1016/j.aogh.2014.09.014
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cervical cancer country profiles. World Health Organization; 2021. Available from: https://www.who.int/publications/m/item/cervical-cancer-country-profiles. Accessed December 23, 2023.
   Google Scholar
• Nakisige C, Schwartz M, Ndira AO. Cervical cancer screening and treatment in Uganda. Gynecol Oncol Rep. 2017;20:37–40. doi:10.1016/j.gore.2017.01.009
   PubMed Web of Science ®Google Scholar
• World Health Organization. Screening as well as vaccination is essential in the fight against cervical cancer. Erişim adresi; 2014. Available from: http://www.who.int/reproductivehealth/topics/cancers/fight-cervical-cancer/en/Erişim.tarihi. Accessed December 23, 2023.
   Google Scholar
• Yee PCG, de Souza P, Khachigian ML. Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 2013;13(2):205–220. doi:10.2174/1568009611313020009
   PubMed Web of Science ®Google Scholar
• Bogani G, Sopracordevole F, Ciavattini A, et al. HPV persistence after cervical surgical excision of high‐grade cervical lesions. Can Cytopathol. 2023. doi:10.1002/cncy.22760
   PubMed Web of Science ®Google Scholar
• Preetha A, Banerjee R, Huilgol N. Surface activity, lipid profiles and their implications in cervical cancer. J Cancer Res Ther. 2005;1(3):180–186. doi:10.4103/0973-1482.19600
   PubMedGoogle Scholar
• Jiang Q, Wang L, Jin M, Shou Y, Zhu H, Li A. The clinical value of lipid abnormalities in early stage cervical cancer. Int J Gene Med. 2022;15:3903–3914. doi:10.2147/IJGM.S352934
   PubMed Web of Science ®Google Scholar
• Serrano M-L, Sánchez-Gómez M, Bravo -M-M. Cervical scrapes levels of insulin-like growth factor-II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Hormone Metab Res. 2010;42(13):977–981. doi:10.1055/s-0030-1267175
   PubMed Web of Science ®Google Scholar
• Ingermann AR, Yang Y-F, Han J, et al. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem. 2010;285(39):30233–30246. doi:10.1074/jbc.M110.122226
   PubMed Web of Science ®Google Scholar
• Mehta HH, Gao Q, Galet C, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011;71(15):5154–5163. doi:10.1158/0008-5472.CAN-10-4513
   PubMed Web of Science ®Google Scholar
• Mohanraj L, Kim H-S, Li W, et al. IGFBP-3 inhibits cytokine-induced insulin resistance and early manifestations of atherosclerosis. PLoS One. 2013;8(1):e55084. doi:10.1371/journal.pone.0055084
   PubMed Web of Science ®Google Scholar
• Min H-K, Maruyama H, Jang BK, et al. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. THE FASEB Journal. 2016;30(12):4071. doi:10.1096/fj.201600427R
   PubMed Web of Science ®Google Scholar
• Kim M, Cai Q, Oh Y. Therapeutic potential of alpha-1 antitrypsin in human disease. Ann Pediatr Endocrinol Metab. 2018;23(3):131. doi:10.6065/apem.2018.23.3.131
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000;36(10):1224–1228. doi:10.1016/S0959-8049(00)00102-7
   PubMed Web of Science ®Google Scholar
• Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(11):3109S–3120S. doi:10.1093/jn/131.11.3109S
   PubMed Web of Science ®Google Scholar
• Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J National Cancer Inst. 2000;92(18):1472–1489. doi:10.1093/jnci/92.18.1472
   PubMed Web of Science ®Google Scholar
• Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J National Cancer Inst. 2002;94(13):972–980. doi:10.1093/jnci/94.13.972
   PubMedGoogle Scholar
• Uganda Ministry of Health. Mbarara Regional Referral Hospital. Uganda Ministry of Health; 2016.
   Google Scholar
• Ahn HK, Shin JW, Ahn HY, et al. Metabolic components and recurrence in early-stage cervical cancer. Tumor Biol. 2015;36(3):2201–2207. doi:10.1007/s13277-014-2831-y
   PubMedGoogle Scholar
• Kim M, Kim I-H, Lim MK, Kim Y, Park B. Increased prevalence of metabolic syndrome in adult cancer survivors: asian first report in community setting. Cancer Epidemiol. 2019;58:130–136. doi:10.1016/j.canep.2018.12.006
   PubMed Web of Science ®Google Scholar
• Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. john wiley & sons; 2013.
   Google Scholar
• Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res. 2003;9(9):3356–3361.
   PubMed Web of Science ®Google Scholar
• Lee SW, Lee SY, Lee SR, Ju W, Kim SC. Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia. J Gynecol Oncol. 2010;21(3):174–180. doi:10.3802/jgo.2010.21.3.174
   PubMed Web of Science ®Google Scholar
• Conover CA, Powell DR. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology. 1991;129(2):710–716. doi:10.1210/endo-129-2-710
   PubMed Web of Science ®Google Scholar
• Ssedyabane F, Ngonzi J, Kajabwangu R, Najjuma JN, Tusubira D, Randall TC. Association between obesity and cervical intraepithelial neoplasia: results from a case control study in south western Uganda. BMC Womens Health. 2023;23(1):1–8.
   PubMed Web of Science ®Google Scholar
• Cohen SS, Park Y, Signorello LB, et al. A pooled analysis of body mass index and mortality among African Americans. PLoS One. 2014;9(11):e111980. doi:10.1371/journal.pone.0111980
   PubMed Web of Science ®Google Scholar
• Bumrungthai S, Ekalaksananan T, Kleebkaow P, et al. Mathematical modelling of cervical precancerous lesion grade risk scores: linear regression analysis of cellular protein biomarkers and human papillomavirus E6/E7 RNA staining patterns. Diagnostics. 2023;13(6):1084. doi:10.3390/diagnostics13061084
   Web of Science ®Google Scholar
• Trabert B, Wentzensen N, Felix AS, et al. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER–medicare linked database. Cancer Epidemiol Biomarkers Prev. 2015;24(1):261–267. doi:10.1158/1055-9965.EPI-14-0923
   PubMed Web of Science ®Google Scholar
• Huang X, Zhao Q, Yang P, et al. Metabolic syndrome and risk of cervical human papillomavirus incident and persistent infection. Medicine. 2016;95:9.
   Web of Science ®Google Scholar
• Molokwu JC, Penaranda E, Lopez DS, et al. Association of metabolic syndrome and human papillomavirus infection in men and women residing in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(8):1321–1327. doi:10.1158/1055-9965.EPI-17-0129
   PubMed Web of Science ®Google Scholar
• Bergerot CD, Costas-Muñiz R, Lee D, Philip EJ. Social Support as a Protective Factor for Patients with Cancer During the Pandemic. Taylor & Francis; 2022:473–474.
   Google Scholar
• Santesso N, Schünemann H, Blumenthal P, et al. World health organization guidelines: use of cryotherapy for cervical intraepithelial neoplasia. Int J Gynecol Obstet. 2012;118(2):97–102. doi:10.1016/j.ijgo.2012.01.029
   PubMed Web of Science ®Google Scholar
• Randall TC, Sauvaget C, Muwonge R, Trimble EL, Jeronimo J. Worthy of further consideration: an updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Preventive Med. 2019;118:81–91. doi:10.1016/j.ypmed.2018.10.006
   PubMed Web of Science ®Google Scholar
• Jacob M, Broekhuizen FF, Castro W, Sellors J. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. Int J Gynaecol Obstet off Organ Int Fed Gynaecol Obstet. 2005;89:S13–20. doi:10.1016/j.ijgo.2005.01.026
   PubMed Web of Science ®Google Scholar
• Luciani S, Gonzales M, Munoz S, Jeronimo J, Robles S. Effectiveness of cryotherapy treatment for cervical intraepithelial neoplasia. Int J Gynaecol Obstet off Organ Int Fed Gynaecol Obstet. 2008;101(2):172–177. doi:10.1016/j.ijgo.2007.11.013
   PubMed Web of Science ®Google Scholar
• Cremer ML, Conzuelo-Rodriguez G, Cherniak W, Randall T. Ablative therapies for cervical intraepithelial neoplasia in low-resource settings: findings and key questions. J Glob Oncol. 2018;4:1–10. doi:10.1200/JGO.18.00093
   PubMedGoogle Scholar
• Pasek M, Suchocka L, Gąsior K. Model of social support for patients treated for cancer. Cancers. 2021;13(19):4786. doi:10.3390/cancers13194786
   PubMed Web of Science ®Google Scholar
• Usta YY. Importance of social support in cancer patients. Asian Pac J Cancer Prev. 2012;13:3569–3572. doi:10.7314/APJCP.2012.13.8.3569
   PubMedGoogle Scholar
• Korotkin BD, Hoerger M, Voorhees S, Allen CO, Robinson WR, Duberstein PR. Social support in cancer: how do patients want us to help? J Psychosoc Oncol. 2019;37(6):699–712. doi:10.1080/07347332.2019.1580331
   PubMed Web of Science ®Google Scholar
• Hofman A, Zajdel N, Klekowski J, Chabowski M. Improving social support to increase QoL in lung cancer patients. Cancer Manage Res. 2021;13:2319–2327. doi:10.2147/CMAR.S278087
   PubMed Web of Science ®Google Scholar
• Mapanga W, Singh E, Feresu SA, Girdler-Brown B. Treatment of pre-and confirmed cervical cancer in HIV-seropositive women from developing countries: a systematic review. Syst Rev. 2020;9:1–16. doi:10.1186/s13643-020-01345-2
   PubMed Web of Science ®Google Scholar
• Arpey NC, Gaglioti AH, Rosenbaum ME. How socioeconomic status affects patient perceptions of health care: a qualitative study. J Prim Care Community Health. 2017;8(3):169–175. doi:10.1177/2150131917697439
   PubMed Web of Science ®Google Scholar
• Vetterlein MW, Löppenberg B, Karabon P, et al. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer. 2017;123(17):3241–3252. doi:10.1002/cncr.30744
   PubMed Web of Science ®Google Scholar
• Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: review of the literature. oncologist. 2015;20(12):1378–1385. doi:10.1634/theoncologist.2015-0110
   PubMed Web of Science ®Google Scholar
• Fraenkel E, Lazurova I. IGF-1 and IGFBP3 as indirect markers of hepatic insulin resistance and their relation to metabolic syndrome parameters in liver steatosis patients. Endoc Regul. 2023;57(1):69–79. doi:10.2478/enr-2023-0009
   PubMedGoogle Scholar
• Adachi Y, Nojima M, Mori M, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and the incidence of malignant neoplasms in a nested case-control study. Cancer Prev Res (Phila). 2020;13(4):385–394. doi:10.1158/1940-6207.CAPR-19-0375
   PubMed Web of Science ®Google Scholar
• Kucera R, Topolcan O, Pecen L, et al. Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic. Clin Chim Acta. 2015;444:271–277. doi:10.1016/j.cca.2015.02.036
   PubMed Web of Science ®Google Scholar
• Pfeffer CM, Singh ATK. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19(2):448. doi:10.3390/ijms19020448
   PubMed Web of Science ®Google Scholar
• Chung S-H, Franceschi S, Lambert P. Estrogen and ERα: culprits in cervical cancer? Trends Endocrinol Metab. 2010;21(8):504–511. doi:10.1016/j.tem.2010.03.005
   PubMed Web of Science ®Google Scholar
• Baker R, Dauner JG, Rodriguez AC, et al. Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine. 2011;53(3):282–285. doi:10.1016/j.cyto.2010.11.014
   PubMed Web of Science ®Google Scholar
• Lee DY, Lee TS. Associations between metabolic syndrome and gynecologic cancer. Obstet Gynecol Sci. 2020;63(3):215–224. doi:10.5468/ogs.2020.63.3.215
   PubMedGoogle Scholar
• Cowey S, Hardy R. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169(5):1505–1522. doi:10.2353/ajpath.2006.051090
   PubMed Web of Science ®Google Scholar
• Raju K, Punnayanapalya SS, Mariyappa N, Eshwarappa SM, Anjaneya C, Kai LJ. Significance of the plasma lipid profile in cases of carcinoma of cervix: a tertiary hospital based study. Asian Pac J Cancer Prev. 2014;15(8):3779–3784. doi:10.7314/APJCP.2014.15.8.3779
   PubMedGoogle Scholar
• Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol. 1997;6(11):863–873.
   PubMed Web of Science ®Google Scholar
• Sun Y, Meng H, Jin Y, et al. Serum lipid profile in gynecologic tumors: a retrospective clinical study of 1550 patients. Eu J Gynaecol Oncol. 2016;37(3):348–352.
   PubMed Web of Science ®Google Scholar
• Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J National Cancer Inst. 1999;91(2):151–156. doi:10.1093/jnci/91.2.151
   PubMed Web of Science ®Google Scholar
• S-H O, Lee O-H, Schroeder CP, et al. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther. 2006;5(11):2685–2695. doi:10.1158/1535-7163.MCT-06-0142
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–518. doi:10.1038/nrc1387
   PubMed Web of Science ®Google Scholar
• Kuhn H, Bräunlich J, Hammerschmidt S, Wirtz H. Candidate genes upregulated in density dependent growth inhibition of lung cancer cells. Int j Oncol. 2004;25(5):1481–1487.
   PubMed Web of Science ®Google Scholar
• Han J-Y, Choi BG, Choi JY, Lee SY, Ju SY. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer. 2006;54(2):227–234. doi:10.1016/j.lungcan.2006.07.014
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet. 1998;351(9113):1393–1396. doi:10.1016/S0140-6736(97)10384-1
   PubMed Web of Science ®Google Scholar
• Chen B, Liu S, Xu W, Wang X, Zhao W, Wu J. IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. J Exp Clin Cancer Res. 2009;28:1–6. doi:10.1186/1756-9966-28-89
   PubMed Web of Science ®Google Scholar
• Adachi Y, Nojima M, Mori M, et al. Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study. Tumor Biol. 2016;37:15125–15132. doi:10.1007/s13277-016-5360-z
   PubMedGoogle Scholar
• Le HT, Lee HJ, Cho J, et al. Insulin-like growth factor binding protein-3 exerts its anti-metastatic effect in aerodigestive tract cancers by disrupting the protein stability of vimentin. Cancers. 2021;13(5):1041. doi:10.3390/cancers13051041
   PubMed Web of Science ®Google Scholar
• Luo Q, Shi W, Dou B, et al. XBP1-IGFBP3 signaling pathway promotes NSCLC invasion and metastasis. Front Oncol. 2021;11:654995. doi:10.3389/fonc.2021.654995
   PubMedGoogle Scholar
• Luo -L-L, Zhao L, Wang Y-X, et al. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma. Sci Rep. 2015;5(1):17336. doi:10.1038/srep17336
   PubMedGoogle Scholar
• Cheung SC, Long X, Liu L, et al. Inhibition of human MCF-7 breast cancer cells and HT-29 colon cancer cells by rice-produced recombinant human insulin-like growth binding protein-3 (rhIGFBP-3). PLoS One. 2013;8(10):e77516. doi:10.1371/journal.pone.0077516
   PubMed Web of Science ®Google Scholar
• Kuhn H, Frille A, Petersen MA, et al. IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients. Transl Oncol. 2023;27:101566. doi:10.1016/j.tranon.2022.101566
   PubMed Web of Science ®Google Scholar
• Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009;94(5):1732–1739. doi:10.1210/jc.2008-2138
   PubMed Web of Science ®Google Scholar
• Gomez J-M, Mourot B, Fostier A, Le Gac F. Growth hormone receptors in ovary and liver during gametogenesis in female rainbow trout (Oncorhynchus mykiss). Reproduction. 1999;115(2):275–285. doi:10.1530/jrf.0.1150275
   Web of Science ®Google Scholar
• Hoyo C, Grubber J, Demark-Wahnefried W, et al. Predictors of variation in serum IGFI and IGFBP3 levels in healthy African American and white men. J Natl Med Assoc. 2009;101(7):711–716. doi:10.1016/S0027-9684(15)30981-0
   PubMed Web of Science ®Google Scholar
• Ssedyabane F, Ngonzi J, Kajabwangu R, Najjuma JN, Tusubira D, Randall TC. Association between obesity and cervical intraepithelial neoplasia: results from a case control study in south western Uganda. BMC Women’s Health. 2023;23(1):1–8. doi:10.1186/s12905-023-02315-1
   PubMed Web of Science ®Google Scholar
• Dassonville O, Formento J, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J clin oncol. 1993;11(10):1873–1878. doi:10.1200/JCO.1993.11.10.1873
   PubMed Web of Science ®Google Scholar
• Gillani SW, Zaghloul HA, Ansari IA, et al. Multivariate analysis on the effects of diabetes and related clinical parameters on cervical cancer survival probability. Sci Rep. 2019;9(1):1084. doi:10.1038/s41598-018-37694-1
   PubMedGoogle Scholar
• Harding JL, Sooriyakumaran M, Anstey KJ, et al. Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J Hypertens. 2016;34(1):149–155. doi:10.1097/HJH.0000000000000770
   PubMed Web of Science ®Google Scholar
• Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011;71(7):2455–2465. doi:10.1158/0008-5472.CAN-10-3323
   PubMed Web of Science ®Google Scholar
• Bochet L, Lehuédé C, Dauvillier S, et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 2013;73(18):5657–5668. doi:10.1158/0008-5472.CAN-13-0530
   PubMed Web of Science ®Google Scholar
• Lin F, Zheng R, Yu C, Su Y, Yan X, Qu F. Predictive role of serum cholesterol and triglycerides in cervical cancer survival. Int J Gynecologic Cancer. 2021;31(2):171–176. doi:10.1136/ijgc-2020-001333
   PubMed Web of Science ®Google Scholar
• Porta C, Marino A, Consonni FM, et al. Metabolic influence on the differentiation of suppressive myeloid cells in cancer. Carcinogenesis. 2018;39(9):1095–1104. doi:10.1093/carcin/bgy088
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Allott EH, Howard LE, Cooperberg MR, et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349–2356. doi:10.1158/1055-9965.EPI-14-0458
   PubMed Web of Science ®Google Scholar
• Lofterød T, Mortensen ES, Nalwoga H, et al. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes. BMC Cancer. 2018;18:1–11. doi:10.1186/s12885-018-4568-2
   PubMed Web of Science ®Google Scholar
• Vernieri C, Pusceddu S, Fucà G, et al. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). Int J Cancer. 2019;144(7):1704–1712. doi:10.1002/ijc.32042
   PubMed Web of Science ®Google Scholar
• Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin. 2011;38(3):243–259. doi:10.1016/j.ucl.2011.04.001
   PubMed Web of Science ®Google Scholar
• Bogani G, Sopracordevole F, Ciavattini A, et al. Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. Eur J Cancer Prev. 2023;32(6):525–532. doi:10.1097/CEJ.0000000000000822
   PubMed Web of Science ®Google Scholar